Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Eylem Sercan Özgür, Cengiz Özge, Ahmet Ïlvan & Sibel Atış Naycı. (2013) Assessment of Long-term Omalizumab Treatment in Patients with Severe Allergic Asthma Long-term Omalizumab Treatment in Severe Asthma. Journal of Asthma 50:6, pages 687-694.
Read now
Read now
David A. Hill & David Artis. (2013) The influence of commensal bacteria-derived signals on basophil-associated allergic inflammation. Gut Microbes 4:1, pages 76-83.
Read now
Read now
Ricardo Tan & Jonathan Corren. (2011) Omalizumab in the treatment of asthma. Expert Review of Respiratory Medicine 5:6, pages 747-756.
Read now
Read now
Articles from other publishers (34)
Vithi Hitendra Patel, Srijani Thannir, Maulik Dhanani, Ivan Augustine, S. L Sandeep, Abdulrahim Mehadi, Chaithanya Avanthika & Sharan Jhaveri. (2023) Current Limitations and Recent Advances in the Management of Asthma. Disease-a-Month 69:7, pages 101483.
Crossref
Crossref
Corrado Pelaia, Giulia Pelaia, Angelantonio Maglio, Caterina Tinello, Luca Gallelli, Nicola Lombardo, Rosa Terracciano & Alessandro Vatrella. (2023) Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis. Journal of Clinical Medicine 12:10, pages 3371.
Crossref
Crossref
Nicola A. Hanania, Robert Niven, Pascal Chanez, Deschildre Antoine, Pascal Pfister, Lorena Garcia Conde & Xavier Jaumont. (2022) Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organization Journal 15:10, pages 100695.
Crossref
Crossref
Corrado Pelaia, Giulia Pelaia, Claudia Crimi, Angelantonio Maglio, Anna Agnese Stanziola, Cecilia Calabrese, Rosa Terracciano, Federico Longhini & Alessandro Vatrella. (2022) Novel Biological Therapies for Severe Asthma Endotypes. Biomedicines 10:5, pages 1064.
Crossref
Crossref
Corrado PELAIA, Giulia PELAIA, Claudia CRIMI, Federico LONGHINI, Nicola LOMBARDO, Rocco SAVINO, Angela SCIACQUA & Alessandro VATRELLA. (2022) Biologics in severe asthma. Minerva Medica 113:1.
Crossref
Crossref
Serafeim Chrysovalantis Kotoulas, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta & Konstantinos Porpodis. (2022) Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine 12:2, pages 165.
Crossref
Crossref
Corrado Pelaia, Claudia Crimi, Santi Nolasco, Giovanna Elisiana Carpagnano, Raffaele Brancaccio, Enrico Buonamico, Raffaele Campisi, Claudia Gagliani, Vincenzo Patella, Girolamo Pelaia, Giuseppe Valenti & Nunzio Crimi. (2021) Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy. Biomedicines 9:12, pages 1822.
Crossref
Crossref
Jean Bousquet, Marc Humbert, Peter G. Gibson, Konstantinos Kostikas, Xavier Jaumont, Pascal Pfister & Francis Nissen. (2021) Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. The Journal of Allergy and Clinical Immunology: In Practice 9:7, pages 2702-2714.
Crossref
Crossref
Corrado Pelaia, Claudia Crimi, Alessandro Vatrella, Caterina Tinello, Rosa Terracciano & Girolamo Pelaia. (2020) Molecular Targets for Biological Therapies of Severe Asthma. Frontiers in Immunology 11.
Crossref
Crossref
Corrado Pelaia, Cecilia Calabrese, Sarah Barbuto, Maria Teresa Busceti, Mariaimmacolata Preianò, Luca Gallelli, Rocco Savino, Alessandro Vatrella & Girolamo Pelaia. (2019) Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study. Pulmonary Pharmacology & Therapeutics 54, pages 25-30.
Crossref
Crossref
Giorgio Lorenzo Colombo, Sergio Di Matteo, Chiara Martinotti, Martina Oselin, Maria Chiara Valentino, Giacomo Matteo Bruno, Claudia Pitotti & Francesco Menzella. (2019) Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review. Therapeutic Advances in Respiratory Disease 13, pages 175346661984135.
Crossref
Crossref
Marco Caminati, Duy Le Pham, Diego Bagnasco & Giorgio Walter Canonica. (2018) Type 2 immunity in asthma. World Allergy Organization Journal 11, pages 13.
Crossref
Crossref
Corrado Pelaia, Cecilia Calabrese, Rosa Terracciano, Francesco de Blasio, Alessandro Vatrella & Girolamo Pelaia. (2018) Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Therapeutic Advances in Respiratory Disease 12, pages 175346661881019.
Crossref
Crossref
Mona Al-Ahmad, Nermina Arifhodzic, Jasmina Nurkic, Ahmed Maher, Tito Rodriguez-Bouza, Nasser Al-Ahmed, Ali Sadek & Edin Jusufovic. (2018) "Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma. Medical Principles and Practice 27:3, pages 260-266.
Crossref
Crossref
F. Paganin, G. Mangiapan, A. Proust, A. Prudhomme, J. Attia, S. Marchand-Adam, F. Pellet, F. Milhe, B. Melloni, A. Bernady, C. Raspaud, C. Nocent, P. Berger & L. Guilleminault. (2017) Lung function parameters in omalizumab responder patients: An interesting tool?. Allergy 72:12, pages 1953-1961.
Crossref
Crossref
Adel H. Mansur, Sapna Srivastava, Verity Mitchell, Julie Sullivan & Ismail Kasujee. (2017) Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. Respiratory Medicine 124, pages 36-43.
Crossref
Crossref
Francesco MenzellaCarla GaleoneDebora FormisanoClaudia CastagnettiPatrizia RuggieroAnna SimonazziLuigi Zucchi. (2017) Real-life Efficacy of Omalizumab After 9 Years of Follow-up. Allergy, Asthma & Immunology Research 9:4, pages 368.
Crossref
Crossref
Hao-Cheng Chen, Chien-Da Huang, Erin Chang & Han-Pin Kuo. (2016) Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. BMC Pulmonary Medicine 16:1.
Crossref
Crossref
Aleksandra Chudzicka, Renata Rożyńska & Adam Wesołowski. (2016) Radykalna poprawa kontroli astmy oskrzelowej po włączeniu do leczenia omalizumabu – opis przypadku. Alergologia Polska - Polish Journal of Allergology 3, pages S10-S13.
Crossref
Crossref
Francesco Menzella, Mirco Lusuardi, Carla Galeone & Luigi Zucchi. (2015) Tailored therapy for severe asthma. Multidisciplinary Respiratory Medicine 10:1.
Crossref
Crossref
Antoine Deschildre, Christophe Marguet, Carole Langlois, Isabelle Pin, Jean-Luc Rittié, Jocelyne Derelle, Rola Abou Taam, Michael Fayon, Jacques Brouard, Jean Christophe Dubus, Daniel Siret, Laurence Weiss, Guillaume Pouessel, Laurent Beghin & Jocelyne Just. (2015) Real-life long-term omalizumab therapy in children with severe allergic asthma. European Respiratory Journal 46:3, pages 856-859.
Crossref
Crossref
Maria R. Bonsignore, Mirella Profita, Rosalia Gagliardo, Loredana Riccobono, Giuseppina Chiappara, Elisabetta Pace & Mark Gjomarkaj. (2015) Advances in asthma pathophysiology: stepping forward from the Maurizio Vignola experience. European Respiratory Review 24:135, pages 30-39.
Crossref
Crossref
Markus Solèr. (2014) Omalizumab for Severe Allergic Asthma: 7 Years and Open Questions. Respiration 88:2, pages 158-161.
Crossref
Crossref
T. Vieira, J.F. de Oliveira & M. da Graça Castel-Branco. (2014) Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal. Allergologia et Immunopathologia 42:1, pages 3-10.
Crossref
Crossref
Piotr Kuna, Anna Bodzenta Łukaszyk, Maciej Kupczyk, Jerzy Kruszewski, Bolesław Samoliński, Izabela Kupryś Lipińska, Iwona Stelmach, Roman Skiepko, Wojciech Budny, Marcin Stobiecki, Małgorzata Rzymkowska, Joanna Jerzyńska, Anna Doboszyńska & Piotr Czerkies. (2014) IV Kliniczne Forum Ekspertów / II Spotkanie Ekspertów – Leczenie Ciężkiej Astmy Alergicznej Omalizumabem. Alergologia Polska - Polish Journal of Allergology 1:1, pages 43-49.
Crossref
Crossref
Olympia A. Tsilochristou, Nikolaos Douladiris, Michael Makris & Nikolaos G. Papadopoulos. (2013) Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?. Pediatric Drugs 15:6, pages 431-440.
Crossref
Crossref
Matthew C. Bell & William W. Busse. (2013) Severe Asthma: An Expanding and Mounting Clinical Challenge. The Journal of Allergy and Clinical Immunology: In Practice 1:2, pages 110-121.
Crossref
Crossref
Francesco Menzella, Nicola Facciolongo, Roberto Piro, Debora Formisano, Alberto Roggeri, Anna Simonazzi, Claudia Castagnetti, Cristiano Carbonelli & Luigi Zucchi. (2012) Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Therapeutic Advances in Respiratory Disease 6:2, pages 87-95.
Crossref
Crossref
David A Hill, Mark C Siracusa, Michael C Abt, Brian S Kim, Dmytro Kobuley, Masato Kubo, Taku Kambayashi, David F LaRosa, Ellen D Renner, Jordan S Orange, Frederic D Bushman & David Artis. (2012) Commensal bacteria–derived signals regulate basophil hematopoiesis and allergic inflammation. Nature Medicine 18:4, pages 538-546.
Crossref
Crossref
Pheidias C. Wu, Jiun-Bo Chen, Shoji Kawamura, Christian Roos, Stefan Merker, Chih-Chin Shih, Ban-Dar Hsu, Carmay Lim & Tse Wen Chang. (2011) The IgE gene in primates exhibits extraordinary evolutionary diversity. Immunogenetics 64:4, pages 279-287.
Crossref
Crossref
Hugo P. S. Van Bever, Bee Wah Lee & Lynette Shek. (2012) Viewpoint: The future of research in pediatric allergy: What should the focus be?. Pediatric Allergy and Immunology 23:1, pages 5-10.
Crossref
Crossref
Eleni G. Tzortzaki, Andreas Georgiou, Dimitrios Kampas, Marinos Lemessios, Miltiadis Markatos, Tonia Adamidi, Katerina Samara, Georgia Skoula, Aggeliki Damianaki, Sophia Schiza, Nikos Tzanakis & Nikolaos M. Siafakas. (2012) Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean “real-life” experience. Pulmonary Pharmacology & Therapeutics 25:1, pages 77-82.
Crossref
Crossref
Kristin Kuhl & Nicola A. Hanania. (2012) Targeting IgE in asthma. Current Opinion in Pulmonary Medicine 18:1, pages 1-5.
Crossref
Crossref
Stephen T. Holgate. (2011) Pathophysiology of asthma: What has our current understanding taught us about new therapeutic approaches?. Journal of Allergy and Clinical Immunology 128:3, pages 495-505.
Crossref
Crossref